skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Selective high-affinity polydentate ligands and methods of making such

Patent ·
OSTI ID:1771755
; ;

This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.

Research Organization:
Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States); Univ. of California, Livermore, CA (United States)
Sponsoring Organization:
USDOE; National Institutes of Health (NIH)
DOE Contract Number:
AC52-07NA27344; CA047829
Assignee:
Lawrence Livermore National Security, LLC (Livermore, CA); The Regents of the University of California (Oakland, CA)
Patent Number(s):
10,874,678
Application Number:
16/289,464
OSTI ID:
1771755
Resource Relation:
Patent File Date: 02/28/2019
Country of Publication:
United States
Language:
English

References (44)

Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes patent-application May 2001
Structure-based hepatitis c virus drug design patent-application September 2003
Spanning binding sites on allosteric proteins with polymer-linked ligand dimers journal October 1998
Discovering High-Affinity Ligands for Proteins: SAR by NMR journal November 1996
Bispecific antibodies that bind to vegf receptors patent-application December 2004
Radioimmunotherapy of lymphoma using anti-CD20 patent January 1997
Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using 131 I-LYM-1 Antibody journal January 1998
Nanomolecular HLA-DR10 Antibody Mimics: A Potent System for Molecular Targeted Therapy and Imaging journal December 2008
Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers patent November 1982
Bispecific antibodies patent-application January 2006
Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma journal August 2007
Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 patent-application October 2002
Bispecific antibodies for selective immune regulation and for selective immune cell binding patent February 1997
Process for the production of hetero-bispecific antibodies patent May 2000
Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity patent January 2000
Bispecific antibodies for inducing apoptosis of tumor and diseased cells patent-application April 2005
Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma journal October 2007
Use of bispecific antibodies to regulate immune responses patent-application April 2003
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials journal January 2001
Disruption of Anthrax Toxin Binding with the Use of Human Antibodies and Competitive Inhibitors journal June 1999
Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof patent July 1991
Treatment of B cell malignancies with131I LYM-1 monoclonal antibodies journal January 1988
Update: Systemic Radiotherapy Can Cure Lymphoma: A Paradigm for Other Malignancies? journal August 2008
Structure-Based Design of a Bispecific Receptor Mimic That Inhibits T Cell Responses to a Superantigen journal April 2001
Lead discovery using molecular docking journal August 2002
Antigenic epitopes with LYM-1 reactivity and uses thereof patent April 2001
AB5 toxins: structures and inhibitor design journal December 2000
Synthesis and Radiolabeling of Selective High-Affinity Ligands Designed to Target Non-Hodgkin's Lymphoma and Leukemia journal May 2007
Bispecific antibodies, methods of production and uses thereof patent September 1999
Direct Antilymphoma Activity of Novel, First-Generation "Antibody Mimics" that Bind HLA-DR10-Positive Non-Hodgkin's Lymphoma Cells journal December 2006
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers patent May 1982
CANCER MODELS: Systems for Identifying New Drugs Are Often Faulty journal November 1997
HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance journal February 2017
Humanization and characterization of the anti-HLA-DR antibody 1D10 journal January 2001
Bispecific antibodies, methods of production and use thereof patent August 2000
Selective high affinity polydentate ligands and methods of making such patent-application April 2006
Bispecific antibodies patent-application June 2005
Identification of Novel Small Molecules That Bind to Two Different Sites on the Surface of Tetanus Toxin C Fragment journal October 2002
Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells journal January 2009
Destruction of contaminating tumor cells in stem cell transplants using bispecific antibodies patent November 1999
Tumor localization and therapy with labeled antibodies to cell surface antigens patent April 1984
Destruction of contaminating tumor cells in stem cell transplants using bispecific antibodies patent April 2001
Method of enhancing the biodistribution of antibody for localization in lesions patent May 1990
Selective high-affinity polydentate ligands and methods of making such patent September 2013

Similar Records

Related Subjects